Abstract
Stage IB2/IIA2 cervical adenocarcinoma patients who received primary radical surgery (RS) had a better disease-free survival (DFS) and overall survival (OS) than those who received preoperative neoadjuvant chemoradiotherapy (NACRT). There was no significant difference when compared to the preoperative neoadjuvant chemotherapy (NACT) group.
Introduction
Cervical adenocarcinoma (AC) accounts for 15–20% of cervical cancer cases, and its incidence is on the rise. Unlike the more common squamous cell carcinoma (SCC), AC is often less sensitive to radiotherapy, which can lead to higher rates of local recurrence and metastasis. For patients with FIGO stage IB2 and IIA2 disease, clinicians often debate the optimal treatment sequence: immediate radical surgery (RS) or neoadjuvant chemotherapy (NACT) or chemoradiotherapy (NACRT) to shrink the tumor first. This retrospective study evaluates which of these three strategies provides the best long-term survival outcomes.
Methods
The researchers analyzed 91 patients treated at the Hunan Cancer Hospital between 2008 and 2015. Patients were divided into three treatment groups: direct radical surgery (RS, n=29), neoadjuvant chemotherapy followed by surgery (NACT+RS, n=24), and neoadjuvant chemoradiotherapy followed by surgery (NACRT+RS, n=38). Survival outcomes were tracked over a median follow-up period of 72 months using Kaplan–Meier estimates and Cox proportional hazard models.
Key Results
The study found a clear survival advantage for patients who underwent direct radical surgery compared to those who received neoadjuvant chemoradiotherapy:
- 5-Year Overall Survival (OS): The RS group achieved a 100% survival rate, significantly higher than the 72.9% observed in the NACRT group (p=0.010).
- 5-Year Disease-Free Survival (DFS): The RS group reached 91.8%, compared to 68.4% in the NACRT group (p=0.016).
While the NACT group also showed lower survival percentages (86.8% OS and 73.7% DFS) than the direct surgery group, these differences did not reach statistical significance (p=0.222 for DFS).
Discussion and Insights
The findings reinforce the clinical observation that adenocarcinoma is relatively radio-resistant compared to SCC. The addition of preoperative radiation (NACRT) did not translate into a survival benefit; instead, these patients had the worst outcomes in the cohort. Multivariate analysis identified lymph node metastasis as the most critical independent prognostic factor for both DFS and OS. If the cancer had spread to the nodes, the 5-year survival rate dropped from approximately 92.7% to 60.8%.
This study suggests that for these specific stages of AC, the delay or biological impact of preoperative therapy—particularly radiation—may not be beneficial. Neoadjuvant therapy is often used to improve operability, but in this cohort, direct surgery provided the best long-term results.
Conclusion and Limitations
Direct radical surgery appears to be the superior treatment strategy for stage IB2/IIA2 cervical adenocarcinoma. However, the authors acknowledge limitations, including the small sample size (n=91) and the retrospective, single-center design, which may introduce selection bias. Larger, multi-center prospective randomized controlled trials are needed to definitively establish the role of neoadjuvant therapy in this patient population.
Summary updated